Tags

Type your tag names separated by a space and hit enter

Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.
J Clin Oncol. 2013 Feb 20; 31(6):731-7.JC

Abstract

PURPOSE

To investigate the frequency and the prognostic role of fibroblast growth factor receptor 1 (FGFR1) amplification in patients with surgically resected squamous cell carcinoma of the lung (SCCL) and the association between smoking and FGFR1 amplification.

PATIENTS AND METHODS

Gene copy number of FGFR1 was investigated in microarrayed tumors from 262 patients with SCCL who had tumor tissue as well as smoking and survival data available. Gene copy number was evaluated by fluorescent in situ hybridization, and an FGFR1-amplified tumor (FGFR1 amp(+)) was prespecified as a tumor with nine or more copies of FGFR1.

RESULTS

Among 262 patients, the frequency of FGFR1 amp(+) was 13.0%. Patients with FGFR1 amp(+) had significantly shorter disease-free survival (DFS; 26.9 v 94.6 months; P < .001) as well as shorter overall survival (OS; 51.2 v 115.0 months; P = .002) than those without FGFR1 amp(+). Multivariate modeling confirmed that patients with FGFR1 amp(+) had a significantly greater risk of recurrence and death than those without FGFR1 amp(+) after adjusting for sex, smoking status, pathologic stage, and adjuvant chemotherapy (DFS: adjusted hazard ratio [AHR], 2.24; 95% CI, 1.45 to 3.45; P < .001; OS: AHR, 1.83; 95% CI, 1.15 to 2.89; P = .01). The frequency of FGFR1 amp(+) was significantly higher in current smokers than in former smokers and never-smokers (28.9% v 2.5% v 0%; P(trend) < .001). As the smoking dosage increased, so did the incidence of FGFR1 amp(+) (P(trend) = .002).

CONCLUSION

FGFR1 amplification is an independent negative prognostic factor in surgically resected SCCL and is associated with cigarette smoking in a dose-dependent manner. FGFR1 amplification is a relevant therapeutic target in Asian patients with SCCL.

Authors+Show Affiliations

Yonsei Cancer Center, Seoul, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23182986

Citation

Kim, Hye Ryun, et al. "Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 31, no. 6, 2013, pp. 731-7.
Kim HR, Kim DJ, Kang DR, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol. 2013;31(6):731-7.
Kim, H. R., Kim, D. J., Kang, D. R., Lee, J. G., Lim, S. M., Lee, C. Y., Rha, S. Y., Bae, M. K., Lee, Y. J., Kim, S. H., Ha, S. J., Soo, R. A., Chung, K. Y., Kim, J. H., Lee, J. H., Shim, H. S., & Cho, B. C. (2013). Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 31(6), 731-7. https://doi.org/10.1200/JCO.2012.43.8622
Kim HR, et al. Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer. J Clin Oncol. 2013 Feb 20;31(6):731-7. PubMed PMID: 23182986.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. AU - Kim,Hye Ryun, AU - Kim,Dae Joon, AU - Kang,Dae Ryong, AU - Lee,Jin Gu, AU - Lim,Sun Min, AU - Lee,Chang Young, AU - Rha,Sun Young, AU - Bae,Mi Kyung, AU - Lee,Young Joo, AU - Kim,Se Hoon, AU - Ha,Sang-Jun, AU - Soo,Ross Andrew, AU - Chung,Kyung Young, AU - Kim,Joo Hang, AU - Lee,Ji Hyun, AU - Shim,Hyo Sup, AU - Cho,Byoung Chul, Y1 - 2012/11/26/ PY - 2012/11/28/entrez PY - 2012/11/28/pubmed PY - 2013/4/16/medline SP - 731 EP - 7 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J. Clin. Oncol. VL - 31 IS - 6 N2 - PURPOSE: To investigate the frequency and the prognostic role of fibroblast growth factor receptor 1 (FGFR1) amplification in patients with surgically resected squamous cell carcinoma of the lung (SCCL) and the association between smoking and FGFR1 amplification. PATIENTS AND METHODS: Gene copy number of FGFR1 was investigated in microarrayed tumors from 262 patients with SCCL who had tumor tissue as well as smoking and survival data available. Gene copy number was evaluated by fluorescent in situ hybridization, and an FGFR1-amplified tumor (FGFR1 amp(+)) was prespecified as a tumor with nine or more copies of FGFR1. RESULTS: Among 262 patients, the frequency of FGFR1 amp(+) was 13.0%. Patients with FGFR1 amp(+) had significantly shorter disease-free survival (DFS; 26.9 v 94.6 months; P < .001) as well as shorter overall survival (OS; 51.2 v 115.0 months; P = .002) than those without FGFR1 amp(+). Multivariate modeling confirmed that patients with FGFR1 amp(+) had a significantly greater risk of recurrence and death than those without FGFR1 amp(+) after adjusting for sex, smoking status, pathologic stage, and adjuvant chemotherapy (DFS: adjusted hazard ratio [AHR], 2.24; 95% CI, 1.45 to 3.45; P < .001; OS: AHR, 1.83; 95% CI, 1.15 to 2.89; P = .01). The frequency of FGFR1 amp(+) was significantly higher in current smokers than in former smokers and never-smokers (28.9% v 2.5% v 0%; P(trend) < .001). As the smoking dosage increased, so did the incidence of FGFR1 amp(+) (P(trend) = .002). CONCLUSION: FGFR1 amplification is an independent negative prognostic factor in surgically resected SCCL and is associated with cigarette smoking in a dose-dependent manner. FGFR1 amplification is a relevant therapeutic target in Asian patients with SCCL. SN - 1527-7755 UR - https://www.unboundmedicine.com/medline/citation/23182986/Fibroblast_growth_factor_receptor_1_gene_amplification_is_associated_with_poor_survival_and_cigarette_smoking_dosage_in_patients_with_resected_squamous_cell_lung_cancer_ L2 - http://ascopubs.org/doi/full/10.1200/JCO.2012.43.8622?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -